CLINICAL TRIALS PROFILE FOR COPPER CU-64 DOTATATE

All Clinical Trials for COPPER CU-64 DOTATATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04234568 ↗	Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-06-29	This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. Giving triapine and lutetium Lu 177 dotatate together may be a good way in treating patients with neuroendocrine tumors.

Clinical Trial Conditions for COPPER CU-64 DOTATATE

Condition Name

Condition Name for COPPER CU-64 DOTATATE
Intervention	Trials
Digestive System Neuroendocrine Tumor	1
Metastatic Well Differentiated Neuroendocrine Neoplasm	1

Condition MeSH

Condition MeSH for COPPER CU-64 DOTATATE
Intervention	Trials
Neuroendocrine Tumors	1

Clinical Trial Locations for COPPER CU-64 DOTATATE

Trials by Country

Trials by Country for COPPER CU-64 DOTATATE
Location	Trials
United States	10

Trials by US State

Trials by US State for COPPER CU-64 DOTATATE
Location	Trials
Ohio	1
Minnesota	1
Massachusetts	1
Kentucky	1
Illinois	1

Clinical Trial Progress for COPPER CU-64 DOTATATE

Clinical Trial Phase

Clinical Trial Phase for COPPER CU-64 DOTATATE
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for COPPER CU-64 DOTATATE
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for COPPER CU-64 DOTATATE

Sponsor Name

Sponsor Name for COPPER CU-64 DOTATATE
Sponsor	Trials
National Cancer Institute (NCI)	1

Sponsor Type

Sponsor Type for COPPER CU-64 DOTATATE
Sponsor	Trials
NIH	1